News on Medial

Bio-tech startup Cellivate Technologies raises $1 Mn in seed round

EntrackrEntrackr · 1y ago
Bio-tech startup Cellivate Technologies raises $1 Mn in seed round
Medial

Bio-tech startup Cellivate Technologies has raised $1 million in a seed round led by Antler along with participation from Venture Catalysts, Hatcher+, and We Founder Circle. The funds will be used to accelerate its R&D efforts, scale up production of its innovative products, and expand its market reach, Cellivate said in a press release. Launched by Viknish Krishnan Kutty, Cellivate is developing innovative solutions to address critical challenges in cell culture and biomanufacturing. The company’s flagship products include advanced microcarriers for scaling up cell growth and a novel cell-based serum designed to replace fetal bovine serum. According to market research, the cell culture market, especially concerning microcarriers and serum, is expected to reach $33 billion by 2030. Cellivate says that its advanced microcarriers and cell-based serum alternatives have the potential to reduce costs, increase efficiency, and address ethical concerns in cell culture processes. Advancements in cell culture and biomanufacturing-related technologies will reduce society’s dependence on animal slaughter since several products/ingredients conventionally derived from animals can be procured from cells.

Related News

Defence-tech startup Ammunic Systems raises $1.1 Mn in seed round

EntrackrEntrackr · 15d ago
Defence-tech startup Ammunic Systems raises $1.1 Mn in seed round
Medial

Defence-tech startup Ammunic Systems raises $1.1 Mn in seed round The proceeds will be channeled towards scaling existing products and building new indigenous defence technologies, Ammunic Systems said in a press release. Defence tech startup Ammunic Systems has raised $1.1 million in a seed funding round co-led by India Accelerator and its multistage VC arm Finvolve. The proceeds will be channeled towards scaling existing products and building new indigenous defence technologies, Ammunic Systems said in a press release. Launched in September 2024, Ammunic Systems is a defence R&D firm focused on the design and development of weapon systems with core competence in advanced electronic fuzes, warheads, and munition integration technologies. The startup aspires to become a next-generation defence and aerospace innovator. The Bengaluru-based startup aims to empower defense with precision and safety and to pioneer tomorrow's warheads for global security. It is committed to providing services that exceed client expectations and help them achieve their business goals. It focuses on research, design, development, and production of new generation weapon systems for current and future warfare. Priyanka Singhal, founder of Ammunic Systems, said, “This investment from India Accelerator is not just capital; it is a vote of confidence in a mission we have poured our hearts into. At Ammunic Systems, we are not just building defence technologies; we are building belief — that India can lead from the front in securing its own future." India Accelerator and Finvolve boast a strong portfolio of defence tech companies including IG Drones, Indrajaal, Zulu Defence, and others.

Genexis Biotech raises Rs 4 Cr in seed round led by GVFL

EntrackrEntrackr · 12d ago
Genexis Biotech raises Rs 4 Cr in seed round led by GVFL
Medial

Genexis Biotech raises Rs 4 Cr in seed round led by GVFL Vadodara-based bio-manufacturing startup Genexis Biotech has raised Rs 4 crore in a seed funding round led by GVFL, with participation from Benzai10. The proceeds will be used to scale bioreactor capacity, build downstream processing infrastructure, launch new recombinant proteins and enzymes, and strengthen compliance, sales, and distribution functions. Genexis Biotech develops animal-origin-free recombinant proteins using precision fermentation, catering to sectors like biopharma, food-tech, and cell culture. The startup operates a certified Class 10,000 facility and is setting up a GMP-compliant unit. It has introduced recombinant peptidases such as amino peptidase and enterokinase, and plans to launch recombinant transferrin and albumin. In the past year, Genexis established partnerships with pharmaceutical companies and biotech firms, signed an MoU with the Gujarat government, and received client orders for alternative protein formulations. It showcased its portfolio at Global Bio-India 2024 and aims to enter the regulated biotech export market, develop encapsulated formulations for the cosmetics industry, and collaborate with CDMOs, academic labs, and biopharma firms. Genexis Biotech focuses on scalable, ethical biomolecule production. GVFL has backed the company as part of its investment thesis across deeptech and biotech innovation.

Download the medial app to read full posts, comements and news.